AZNAstraZeneca PLC
Is it safe?
Nothing alarming, nothing pristine: insiders buying, comfortable debt (A), and typical volatility.
Insiders were net buyers (+$3K, 90 days to Oct 22, 2026). SEC Form 4 filings: officers and directors must report their own trades within two business days.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -28% · now 18% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can AZN take a bad year?
AstraZeneca PLC carries $28.6B of net debt as at Q2 2025.
Net debt · as at Q2 2025 · debt less the cash on hand
- Debt / equity
- 0.80×
Debt / equity
- Annualised volatility
- 27%
Annualised volatility · S&P 500 16% · noticeably more jumpy than the market
- Worst drawdown on file
- −28%
Worst drawdown on file · −18% today
Details›
- Total debtQ2 2025
- $35.7B
- Cash and short-term investments
- $7.06B
- Net debt
- $28.6B
- Debt / equity
- 0.80×
- Annualised volatilitytwo years of daily moves
- 27%
- Worst drawdown on file
- −28%
- Below its 52-week high
- 18%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.
Drug Manufacturers, General
Ranks #5 of 7 by RyuScore